Answers are grounded in this paper and cite their sources.
Case report shows improved outcomes in a patient with hepatic encephalopathy using amino acid therapy, suggesting potential for broader applications.
We treated a 68-year-old male patient of hepatic encephalopathy with oral branchedchain amino acids-enriched formula (Aminoleban EN) in addition to lactulose. His encephalopathy was successfully controlled with this therapy for more than a year despite the high blood ammonia levels. Repeated amino acids analyses demonstrated that the deranged branched chain to aromatic amino acids ratio was attenuated with long-term Aminoleban EN administration both in plasma and in cerebrospinal fluid. Oral branched-chain amino acid supplement was very useful in improving the chronic portosystemic or hepatic encephalopathy in this patient.
No takes yet. Share an insight, caveat, or question.
Fukuda et al. (1999) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: